Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. WEIGHT-LOSS MEDICATIONS MAY ALSO BENEFIT COMMON ...

"This study allowed us to do a direct comparison ... to choose a weight-loss medication that matches the patient’s personal goals and health status. "Both Wegovy and Zepbound have demonstrated ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo ... a 25% or more body weight reduction due to tirzepatide. By comparison, those who received semaglutide experienced a 16% ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Although GLP-1 drugs offer many health benefits, their high cost has created an affordability crisis for patients. With a ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Zepbound is a weekly injectable prescription weight loss medication with the active ingredient tirzepatide. It’s a GLP-1 agonist drug that slows stomach emptying, meaning you feel fuller for longer.